Everolimus Data for Seizures in Tuberous Sclerosis 'Exciting'

Pauline Anderson

April 21, 2016

Results of a randomized, placebo-controlled, phase 3 trial showed that everolimus (Afinitor, Novartis) — an oral agent developed as a cancer drug — significantly reduced seizure frequency in patients with treatment-resistant tuberous sclerosis complex (TSC).

A rare genetic disorder caused by overactivation of the mammalian target of rapamycin (mTOR) pathway that promotes cell growth, TSC leads to seizures, cortical malformations, and neuronal hyperexcitability. A common feature is subependymal giant cell astrocytomas (SEGAs).

The results, though, may have much broader implications for the treatment of epilepsy.

"I have to emphasize to you what a big leap this is," Jacqueline French, MD, professor, neurology and co-director, epilepsy research and epilepsy clinical trials, NYU Comprehensive Epilepsy Center, New York, told Medscape Medical News.

Dr Jacqueline French

"Up until now, we have not treated anybody for their epilepsy; we have only treated them for their seizures. We have given them drugs that suppress their seizures, but we have not fundamentally changed the mechanism underlying that, which caused the epilepsy."

Everolimus is proving to be successful in TSC, but it might also be useful for some cortical dysplasias and other types of epilepsy, she said.

"This might be a first step," said Dr French, who was the global principal investigator for EXIST-3 (EXamining everolimus In a Study of TSC).

She presented the results here during the American Academy of Neurology (AAN) 2016 Annual Meeting. EXIST-3 was sponsored by Novartis Pharmaceuticals.

The study included 366 patients with TSC with a median age of 10 years (range, 2 - 65 years). They had to have had at least 16 treatment-resistant seizures and were receiving 1 to 3 antiepileptic drugs (AEDs) at stable doses. In about half of the patients, 6 or more AEDs had failed before enrollment.

Many patients had also tried other treatment approaches, including the high-fat, low-carbohydrate ketogenic diet and vagus nerve stimulation.

The overall median baseline seizure frequency per 28 days was 37.5. The study didn't restrict the type of seizures, so patients had tonic-clinic, atonic, clonic, myoclonic, and several other seizure types.

After an 8-week baseline phase, patients were randomly assigned to receive, in addition to their AEDs, placebo, lower-dose everolimus (3 - 7 ng/mL), or higher-dose everolimus (9 - 15 ng/mL).

After a 6-week titration phase, patients completed a 12-week maintenance phase.

The dropout rate throughout the trial was "on the lower side compared to other AED trials," according to Dr French; only 5 in the placebo group, 7 in the low-dose treatment group, and 8 in the higher-dose treatment group discontinued treatment.

Responder Rate

The study showed that 15.1% of the placebo group, 28.2% of the low-dose everolimus (P = .008 vs placebo), and 40% of the high dose everolimus group (P < .001 vs placebo) attained the primary endpoint of a 50% responder rate.

The treatment also came out on top for the other primary endpoint, percentage reduction in seizure frequency: 14.9% for placebo, 29.3% for low dose (P = .003 vs placebo) and 39.6% for the high dose (P < .001 vs placebo).

"Whether looking at one or the other primary outcome, the results were statistically significant, and there was a dose-response relationship," said Dr French.

"The data suggests that if patients can tolerate a higher dose then a higher dose is going to produce more improvement in seizures."

Across all percentages of seizure freedom, the placebo patients "as you might expect, had a greater likelihood of worsening" and patients taking everolimus "were more likely to improve," said Dr French.

"It was very unlikely that placebo would render patients seizure-free," commented Dr French. Total seizure freedom was achieved by 0.8% of the placebo, compared with 5.1% for the low-dose and 3.8% for the high-dose treatment groups.

When asked whether the higher seizure freedom rate in the lower dose was important, Dr French said she didn't think it was "a real difference" and might change during the later extension phase.

The three study groups had a similar safety profile. Adverse events (AEs) were consistent with known risks associated with the drug. The most common ones were stomatitis, diarrhea, mouth ulceration, nasopharyngitis, and upper respiratory tract infection.

"This is not a new drug; it's been around a long time and these are the expected AEs," commented Dr French.

Perhaps the "most problematic" side effects were the ulcers in the mucus membrane of mouth, said Dr French. "But there are ways to treat those and they come and go, so it's not like you have one forever."

And the fact that there were so few dropouts "suggests that they were manageable and tolerable."

Hematologic and biochemical AEs included neutropenia, hypercholesterolemia, elevated alanine aminotransferase levels, and hypertriglyceridemia.

"These are things you don't usually see with AEDs," noted Dr French. "We have to be looking out for these when we use everolimus for this indication."

Extension Phase

Most of the patients have now been entered into the open-label extension phase of the trial. During this phase, the blind is broken, and treating physicians determine the dose of everolimus.

Researchers will soon be in a position to determine whether the improvement in seizures has continued during this extension phase, said Dr French.

Whether this drug proves to be disease-modifying for epilepsy with continued therapy producing a continued improvement "remains to be seen," she added.

Although 15 ng/mL is currently the top dose being used, "it could be that some children will tolerate more than that," she said.

It's not clear whether children could take this drug indefinitely "We will have to see what happens over time," said Dr French. But she pointed out that many of the kids have taken the drug for several years as they were enrolled in a previous trial of the drug for SEGAs.

Although this is still to be analyzed and verified, Dr French said "there is a hint" that the earlier that patients start the drug, the more benefits they get. It's possible, she said, that earlier initiation may help ward off sometimes severe developmental delays.

"The ideal would be to treat as early as possible, before you had the burden of cognitive dysfunction," said Dr French. "But again, it's very early days. The first thing we had to do was say that it works."

And the fact that this new study shows that it does work is "very exciting," said Dr French.

"In the epilepsy world, it's a big deal because it's where we want to go with epilepsy therapy in general — you don't want to be masking or suppressing the seizures; you want to be treating the epilepsy, and it's something we never have been able to do."

It's possible that other types of epilepsy are related to abnormalities of the mTOR pathway, including some focal cortical dysplasias.

"Although I am standing here today talking to you about tuberous sclerosis, it could be that this pathway and interventions in this pathway will be very important for other common forms of epilepsy as well," Dr French told delegates to a Clinical Trials Plenary session during the AAN meeting.

The more researchers learn about the genetics of epilepsy and the different pathways involved with the condition, "the more we can say 'okay, we aren't just going to give Dilantin [phenytoin] to everybody', we are going to fit the treatment with the underlying condition, and to us that is Nirvana."

Asked to comment, Steven Wolf, MD, director of pediatric epilepsy, Mount Sinai-Beth Israel Medical Center & St. Luke's–Roosevelt Hospital, New York, said he and his colleagues were "extremely excited" at seeing the study.

"We feel this drug is a wonderful addition to treating patients with intractable epilepsy," said Dr Wolf.

Although these experts have long felt that this drug might have some benefit for TSC, "we had no real hard data" to present to families, he said.

"There has been a reluctance by some TS families to start Afinitor just for SEGA and renal tumors, but the seizure indication might help get more families to consider treatment," said Dr Wolf.

"It's great news that we not only can recommend this medication for decreasing the size of SEGA's, but also to help reduce the seizure burden." 

This represents "a big step" in helping patients with TSC and difficult-to-control seizures, he said.

The study was funded by Novartis Pharmaceuticals. Dr French received salary support to NYU from the Epilepsy Study Consortium for consultant time related to Acorda, Alexza, Anavex, BioPharm Solutions, Concert Pharmaceuticals, Eisai, Georgia Regents University, GW Pharma, Marinus, Monteris, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SciFluor, SK Life Sciences, Sunovion, Takeda, UCB Inc, Upsher Smith, Xenon Pharma, and Zogenix. She received research funding from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK Life Sciences, UCB, Upsher-Smith, Vertex, NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, and Epilepsy Study Consortium.

American Academy of Neurology (AAN) 2016 Annual Meeting. Abstract 32430. Presented April 20, 2016. 


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.